After confirmation of tumor growth, cancer-bearing and non-cancer mice received combinatorial treatment of anti-CTLA-4 (1 mg per dose, twice per week) and anti-PD-1 (200 μg per dose, thrice per week) for three weeks. This evidence concerns the gene PDCD1 and neoplasm.